Nuo Therapeutics, Inc.
AURX · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 47.4% | 44.6% | 22.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $0 | $0 |
| % Margin | 60.6% | 77.2% | 75% | 78.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -52.3% | -93.1% | -153.8% | -159.4% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$0 |
| % Margin | -52.1% | -92.8% | -154% | -125.8% |
| EPS | -0.01 | -0.014 | -0.016 | -0.011 |
| % Growth | 28.1% | 12.6% | -50% | – |
| EPS Diluted | -0.01 | -0.014 | -0.016 | -0.011 |
| Weighted Avg Shares Out | 48 | 47 | 47 | 47 |
| Weighted Avg Shares Out Dil | 48 | 47 | 47 | 47 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | -48.1% | -87.3% | -153.8% | -152.2% |